The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record, with a small difference in title or year; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical and 1 additional prospective ADT. The study comprised a 7-28-day screening, an 8-week prospective treatment, and a 6-week randomization phase. During prospective treatment, patients experiencing a major depressive episode (17-item Hamilton Rating Scale for Depression total score > or = 18) received single-blind adjunctive placebo plus clinicians' choice of ADT (escitalopram, fluoxetine, paroxetine controlled-release, sertraline, or venlafaxine extended-release). Subjects with inadequate response were randomized to adjunctive placebo (n = 190) or adjunctive aripiprazole (n = 191) (starting dose 5 mg/d, dose adjustments 2-20 mg/d, mean end-point dose of 11.0 mg/d). The primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale total score from end of prospective treatment phase to end of randomized treatment phase (last observation carried forward). Mean change in Montgomery-Asberg Depression Rating Scale total score was significantly greater with adjunctive aripiprazole than placebo (-8.5 vs -5.7; P = 0.001). Remission rates were significantly greater with adjunctive aripiprazole than placebo (25.4% vs 15.2%; P = 0.016) as were response rates (32.4% vs 17.4%; P < 0.001). Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4.2% vs 25.9%), headache (10.5% vs 9.0%), and fatigue (3.7% vs 10.1%). Incidence of adverse events leading to discontinuation was low (adjunctive placebo [1.1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of augmentation with AAs has been supported by many clinical studies for aripiprazole,(Berman et al., 2007; Marcus et al., 2008) olanzapine+fluoxetine (Corya et al., 2006; Shelton et al., 2010; Shelton and Papakostas, 2008; Thase et al., 2007), quetiapine (El-Khalili et al., 2010; McIntyre et al., 2007)) and risperidone (Keitner et al., 2009; Mahmoud et al., 2007).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Marcus et al., 2008
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“The primary efficacy endpoint was the mean change from end of the prospective treatment phase to the end of the randomized, double-blind phase in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.(18) A key secondary endpoint was the change in mean Sheehan Disability Scale (SDS) scores during the rando…”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“Other secondary efficacy measures included the CGI-I and CGI Severity of Illness (CGI-S),(20) the Inventory of Depressive Symptomatology Self-Report Scale (IDS-SR),(21) and the Quick Inventory of Depressive Symptoms Self-Report Scale (QIDS-SR).(22) Safety was evaluated by monitoring of adverse events (AEs), body weigh…”
MethodSelf-citationA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationA Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170 · cited 2×
“In addition, extrapyramidal symptoms rating scale evaluations included changes in Simpson-Angus Scale,(23) the Abnormal Involuntary Movement Scale,(24) and the Barnes Akathisia Clinical Assessment.(25) The selfreported Massachusetts General Hospital Sexual Functioning Inventory (SFI) Scale was also evaluated.”
MethodDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 7×
“Patients were also required to have reported an inadequate response to previous ADT, as determined by the Antidepressant Treatment Response Questionnaire.1 Specifically, inadequate response was defined as the patients’ reporting of <50% reduction in severity of depression to at least 1 and no more than 3 ADT trials of…”
BackgroundMethodAripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Psychosocial Disability During the Long-term Course of Unipolar Major Depressive Disorder
Judd, L. L., Akiskal, H. S., Zeller, P. J., Paulus, M., Leon, A. C., Maser, J. D., Endicott, J., Coryell, W., Kunovac, J. L., Mueller, T. I., et al. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.4.375 · Cited by 593 · cited 1×
“These findings are important, given the known impact of residual symptoms on impaired psychosocial functioning.(29,30) Although improvements in work/school functioning were not significant, 6 weeks may be too short to detect improvement in this area.”
BackgroundThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409 · cited 5×
“conducted as previously described.(17) All statistical tests are interpreted at the 5% significance level.”
BackgroundMethodResultSelf-citationAssessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319 · cited 2×
“A key secondary endpoint was the change in mean Sheehan Disability Scale (SDS) scores during the randomized, double-blind phase.(19) The SDS evaluates the extent to which depression interferes with work, family, and social life; each aspect is scored on a scale of 1–10, and a mean score of 1–10 is generated from the i…”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Self-citationRapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., Turkoz, I., Lasser, R. A., Loescher, A., Bouhours, P., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301113 · Cited by 168
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
Augmentation and combination strategies in treatment-resistant depression.
Fava, M. (2001) · PubMed · Cited by 153
Fava, M., & Rush, A. J. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091771 · Cited by 151 · cited 1×
“inadequate antidepressant response or to increase the chance of achieving remission.(2) In particular, atypical antipsychotics”
BackgroundStark, A. D., Jordan, S., Allers, K. A., Bertekap, R. L., Chen, R., Kannan, T. M., Molski, T. F. P., Yocca, F. D., Sharp, T., Kikuchi, T., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0621-y · Cited by 148
Three- to 5-year prospective follow-up of outcome in major depression
VAN LONDEN, L., MOLENAAR, R. P. G., GOEKOOP, J. G., ZWINDERMAN, A. H., & ROOIJMANS, H. G. M. (1998) · Psychological Medicine · doi:10.1017/s0033291797006466 · Cited by 126 · cited 1×
“These findings are important, given the known impact of residual symptoms on impaired psychosocial functioning.(29,30) Although improvements in work/school functioning were not significant, 6 weeks may be too short to detect improvement in this area.”
BackgroundPapakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., Fava, M., & Nierenberg, A. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1017 · Cited by 125
Worthington, J. J., Kinrys, G., Wygant, L. E., & Pollack, M. H. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200501000-00002 · Cited by 120
Labbate, L. A., & Lare, S. B. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056257 · Cited by 104 · cited 1×
“The selfreported Massachusetts General Hospital Sexual Functioning Inventory (SFI) Scale was also evaluated.(26) The randomized sample comprised all patients whowere randomized in the double-blind treatment phase; the safety sample included those randomized patients who received at least 1 dose of double-blind study m…”
MethodSimon, J. S., & Nemeroff, C. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1002 · Cited by 103
Self-citationAn Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression
Patkar, A. A., Peindl, K. S., Mago, R., Mannelli, P., & Masand, P. S. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0205 · Cited by 63
Aripiprazole Augmentation in Treatment-Resistant Depression
Barbee, J. G., Conrad, E. J., & Jamhour, N. J. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490521954 · Cited by 54
Papakostas, G. I., Miller, K. K., Petersen, T., Sklarsky, K. G., Hilliker, S. E., Klibanski, A., & D, M. F. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0612 · Cited by 48 · cited 1×
“Taken together, these findings suggest that aripiprazole augmentation does not worsen any potential for hyperprolactinemia that has been suggested following treatment with selective serotonin reuptake inhibitors.(31) Strengths of the current study include the large patient population, the randomized and placebo-contro…”
BackgroundAdson, D. E., Kushner, M. G., & Fahnhorst, T. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.11.007 · Cited by 48
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response
Pae, C., Patkar, A. A., Jun, T., Lee, C., Masand, P. S., & Paik, I. (2006) · Depression and Anxiety · doi:10.1002/da.20244 · Cited by 41
Research works printed but not linked: 1
- Fava, 2001, J Clin Psychiatry, 62, 4
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“These are generally administered at much lower doses than those recommended for schizophrenia and bipolar disorder (Berman et al., 2007; Marcus et al., 2008; Philip et al., 2008) but this practice is off-label and these agents are not formally indicated for augmentation.”
BackgroundMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Augmentation with aripiprazole was found to be signifi cantly more benefi cial compared to antidepressant alone but caused more unwanted effects (weight gain and EPMS) (studies included: Berman et al. 2007, 2009; Marcus et al. 2008).”
BackgroundNelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
“(10) 2008 Aripiprazole SSRI/SNRI 369 6 1–3 historical trials and one prospective trial MADRS Berman et al.”
Background
Metadata
- Authors
- Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Otsuka (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sherbrooke Research and Development Centre (CA)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Marcus, Ronald N.
- Thase, Michael E.
- Berman, Robert M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-04
- Volume
- 28
- Issue
- 2
- Pages
- 156-165
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2007880575
- Cited by
- 518
- References
- 29
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 13 · 2022: 11 · 2021: 13 · 2020: 172 · 2019: 11 · 2018: 19 · 2017: 13 · 2016: 15 · 2015: 24 · 2014: 27 · 2013: 34 · 2012: 20
- FWCI
- 28.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- aripiprazole, major depressive disorder, adjunctive therapy, antidepressant non-response, atypical antipsychotics, akathisia, remission, treatment-resistant depression, antidepressant side effects
- MeSH terms
- Aripiprazole, Venlafaxine Hydrochloride, Adult, Antidepressive Agents, Cyclohexanols, Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Fatigue, Female, Fluoxetine, Humans, Male, Middle Aged, Piperazines, Prospective Studies, Psychiatric Status Rating Scales, Time Factors, Citalopram, Quinolones, Weight Gain, Single-Blind Method, Treatment Outcome, Akathisia, Drug-Induced, Paroxetine, Sertraline, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.